TABLE 1.
Guidelines
| Indication | Organization | Year | Wording | Population | Gleason | PSA | T stage | Other |
| Initial staging | AUA, ASTRO, SUO | 2017 | “Should consider staging with bone scan” (expert opinion) | Intermediate-risk | 7 or | 10–20 or | T2b–T2c | — |
| “Should stage with bone scan” (clinical principle) | High-risk | ≥8 or | >20 or | T3–T4 | — | |||
| NCCN | 2018 | “Staging work-up with bone scan if” | Intermediate-risk | — | >10 and | T2 | — | |
| “Staging work-up with bone scan if” | High-risk | ≥8 or | >20 or | T3–T4 | — | |||
| “Staging work-up with bone scan if” | — | — | — | — | Bone symptom | |||
| ACR | 2017 | “May be appropriate” | Intermediate-risk | — | >10 and | T2 | — | |
| “Usually appropriate” | High-risk | ≥8 or | >20 or | T3–T4 | — | |||
| “Usually appropriate” | — | — | — | — | Bone symptom | |||
| SNMMI | 2017 | “May be appropriate” | Low-risk | — | — | — | Elevated PAL | |
| “May be appropriate” | Intermediate-risk | 7 or | 10–20 or | T2b–T2c | — | |||
| “Appropriate” | Intermediate-risk | 7 and | 10–20 and | T2b–T2c | — | |||
| “Appropriate” | High-risk | ≥8 or | >20 or | T3–T4 | — | |||
| “Appropriate” | — | — | — | — | Bone symptom | |||
| Biochemical recurrence localization, restaging, posttreatment follow-up | AUA, ASTRO | 2013 | “Restaging may be considered (Option; Grade C)” | After radical prostatectomy | — | — | — | — |
| NCCN | 2018 | “Consider restaging with bone imaging” | After radical prostatectomy | — | — | — | — | |
| “Restaging with bone imaging if” | After definitive radiation therapy | — | — | — | — | |||
| “Monitoring with bone scan every 6–12 mo if” | Localized under observation | — | — | — | Bone symptom | |||
| “Monitoring with bone scan every 6–12 mo if” | N1/M1 under systemic therapy | — | — | — | Bone symptom | |||
| ACR | 2017 | “May be appropriate” | After radical prostatectomy | — | — | — | — | |
| 2017 | “May be appropriate” | After nonsurgical treatment | — | — | — | — | ||
| “Usually appropriate” | N1/M1 under systemic therapy | — | — | — | — | |||
| SNMMI | 2017 | “Appropriate” | — | — | — | — | Treatment change is planned | |
| “Appropriate” | — | — | — | — | Bone symptom | |||
| “Appropriate” | — | — | — | — | Before bone RNT | |||
| “Appropriate” | — | — | — | — | Equivocal imaging findings |
SNMMI = Society of Nuclear Medicine and Molecular Imaging; ACR = American College of Radiology; SUO = Society of Urologic Oncology; AUA =American Urological Association; ASTRO = American Society for Radiation Oncology; PAL = phosphatase alkaline; RNT = radionuclide therapy.